10x Genomics (TXG) Enterprise Value (2018 - 2026)

10x Genomics has disclosed Enterprise Value across 9 years of filings, most recently posting -$539.8 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$539.8 million, down 26.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$539.8 million (down 26.46% YoY), and the FY2025 annual result was -$523.4 million, down 33.05% from the prior year.
• Enterprise Value came in at -$539.8 million for Q1 2026 at 10x Genomics, down from -$523.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$222.4 million in Q4 2022 to a low of -$539.8 million in Q1 2026.
• The 5-year median for Enterprise Value is -$391.4 million (2023), against an average of -$394.4 million.
• Across the five-year window, Enterprise Value jumped 62.21% in 2022 and plunged 74.79% in 2023, its largest moves.
• 10x Genomics' Enterprise Value stood at -$222.4 million in 2022, then slumped by 74.79% to -$388.7 million in 2023, then slipped by 1.21% to -$393.4 million in 2024, then tumbled by 33.05% to -$523.4 million in 2025, then slipped by 3.14% to -$539.8 million in 2026.
• The last three Enterprise Value figures came in at -$539.8 million (Q1 2026), -$523.4 million (Q4 2025), and -$482.1 million (Q3 2025), per Business Quant data.